-+ 0.00%
-+ 0.00%
-+ 0.00%

Xilio plans IND filing in 2027 for masked CLDN18.2 T-cell engager XTX601

PUBT·04/17/2026 20:01:17
Listen to the news
Xilio plans IND filing in 2027 for masked CLDN18.2 T-cell engager XTX601
  • Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager targeting CLDN18.2, scheduled for presentation at AACR Annual Meeting on Apr. 20, 2026.
  • Preclinical studies showed tumor-selective activation with strong anti-tumor activity across multiple CLDN18.2-expressing solid tumor models.
  • Non-human primate testing indicated favorable tolerability, supporting a potentially wider therapeutic window than non-masked approaches.
  • Xilio plans to move XTX601 into IND-enabling studies, targeting an IND submission in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171601PRIMZONEFULLFEED9692033) on April 17, 2026, and is solely responsible for the information contained therein.